Eye-Preserving Therapies for Advanced Retinoblastoma
Chuandi Zhou,Xuyang Wen,Yi Ding,Jingwen Ding,Mei Jin,Zhenyin Liu,Sha Wang,Minglei Han,Hongfeng Yuan,Yishuang Xiao,Li Wu,Jiancang Wang,Yangjun Li,Jiawei Yu,Yuechun Wen,Juan Ye,Rong Liu,Zhijun Chen,Shangcai Xue,Wei Lu,Hongfei Liao,Jizhe Cui,Dan Zhu,Fang Lu,Song Tang,Yu Wu,Tseden Yangkyi,Guanghong Zhang,Miershalijiang Wubuli,Huiyu Guo,Xian Wang,Yanjin He,Xunlun Sheng,Qing Wang,Yingxiu Luo,Jiayan Fan,Jinlei Qi,Zhangsheng Yu,Jia Tan,Jianhong Liang,Xiantao Sun,Liwen Jin,Xinji Yang,Jing Zhang,Xunda Ji,Junyang Zhao,Renbing Jia,Xianqun Fan
DOI: https://doi.org/10.1016/j.ophtha.2021.09.002
IF: 14.277
2022-02-01
Ophthalmology
Abstract:PurposeMultiple eye-preserving treatments have been widely used in China for the last 15 years, however, controversy remains on using eye-preserving therapies for advanced retinoblastoma (The International Intraocular Retinoblastoma Classification: groups D and E). This study attempts to estimate the impact of eye-preserving therapies for the long-term prognosis of advanced retinoblastoma with regard to overall survival and ocular salvage.DesignA retrospective cohort study covering all 31 provinces (38 retinoblastoma treating centers) of Chinese mainland.ParticipantsA total of 1678 patients diagnosed with groups D or E retinoblastoma from January 2006 to May 2016.MethodsMedical charts review was performed. The patients were divided into primary enucleation and eye-preserving groups, and they were followed up for survival status. The impact of initial treatment on survival was evaluated by Cox analyses.Main Outcome MeasuresOverall survival and final eye-preservation rate.ResultsAfter a median follow-up period of 43.9 months, 196 (12%) patients died, and the 5-year overall survival was 86%. In total, the eyeball preservation rate was 48%. In this cohort, 1172 (70%) patients had unilateral retinoblastoma, whereas 506 (30%) were bilateral. For unilateral patients, 570 (49%) eyes had primary enucleation, and 602 (51%) patients had eye-preserving therapies initially. During the follow-up (median: 45.6 months), 59 (10%) patients from primary enucleation group and 56 (9.3%) patients from eye-preserving group died. Multivariate Cox analyses indicated no significant difference in overall survival between the two groups (HR=1.25; 95%CI:0.85-1.84; p=0.250). For bilateral patients, only 95 (19%) eyes had primary enucleation, and 411 (81%) patients had eye-preserving therapies initially. During the follow-up (median: 40.1 months), 12 (13%) patients from primary enucleation group and 69 (17%) patients from eye-preserving group died. For bilateral retinoblastoma with the worse eye of group E, patients had primary enucleation exhibited better overall survival (HR=2.35; 95%CI:1.10-5.01; p=0.027), however, this survival advantage was not evident until passing 22.6 months after initial diagnosis.ConclusionEye-preserving therapies have been widely used for advanced retinoblastoma in China. Bilateral patients with the worse eye of group E initially underwent eye-preserving therapies exhibited a worse overall survival. The choice of primary treatment for advanced retinoblastoma should be carefully weighed.
ophthalmology